CYAD News

Celyad, a Belgian biotech developing gene therapies for cardiovascular diseases and cancer, raised $100 million by offering 1.5 million shares (upsized from 1.4 million) at $68.56, below the $71.13 closing price on Thursday on the Euronext. The offering consisted of 1.2 million ADSs, which will trade on the NASDAQ under the symbol CYAD, and 0.3 million common shares, which will...read more

Celyad, a Belgian biotech developing gene therapies for cardiovascular diseases and cancer, announced terms for its IPO on Monday. The Mont-Saint-Guibert, Belgium-based company plans to raise $99 million by offering 1.4 million shares at $70.98 per share. At IPO price, Celyad would command a fully diluted market value of $674 million.  Celyad, which was founded in 2007,...read more

Celyad, a Belgian biotech developing gene therapies for cardiovascular diseases and cancer, filed on Monday with the SEC to raise up to $115 million in an initial public offering. Celyad's stock is currently traded on the Euronext Brussels and Euronext Paris under the symbol CYAD. Its market cap is about €450 million and it gained 5% on Monday. The...read more